Bowen Acquisition Corp Receives NASDAQ Delisting Notification for Failure to Comply with Listing Requirements
Bowen Acquisition Corp (NASDAQ: BOWN), a special purpose acquisition company, received a delisting determination letter from Nasdaq on July 15, 2025, due to multiple listing requirement violations. The company failed to maintain: $50 million minimum market value of listed securities, 1.1 million publicly held shares, $15 million market value of publicly held shares, and 400 total shareholders.
BOWN has until July 22, 2025, to appeal the decision to a Nasdaq Hearings Panel. Without an appeal, trading will be suspended on July 24, 2025. The company intends to request a hearing and a trading suspension stay while pursuing its planned business combination with Shenzhen Qianzhi BioTechnology Co. Ltd.
Bowen Acquisition Corp (NASDAQ: BOWN), una società di acquisizione a scopo speciale, ha ricevuto una lettera di determinazione di esclusione da Nasdaq il 15 luglio 2025, a causa di molteplici violazioni dei requisiti di quotazione. La società non è riuscita a mantenere: un valore minimo di mercato di 50 milioni di dollari per i titoli quotati, 1,1 milioni di azioni detenute dal pubblico, un valore di mercato di 15 milioni di dollari per le azioni detenute dal pubblico e 400 azionisti totali.
BOWN ha tempo fino al 22 luglio 2025 per fare appello alla decisione presso un Panel di Udienze di Nasdaq. In assenza di appello, la negoziazione verrà sospesa il 24 luglio 2025. La società intende richiedere un'udienza e una sospensione della sospensione delle negoziazioni mentre prosegue con la prevista combinazione aziendale con Shenzhen Qianzhi BioTechnology Co. Ltd.
Bowen Acquisition Corp (NASDAQ: BOWN), una compañía de adquisición con propósito especial, recibió una carta de determinación de exclusión de Nasdaq el 15 de julio de 2025 debido a múltiples incumplimientos de los requisitos de cotización. La compañía no logró mantener: un valor mínimo de mercado de 50 millones de dólares en valores cotizados, 1.1 millones de acciones en manos del público, un valor de mercado de 15 millones de dólares en acciones públicas y 400 accionistas totales.
BOWN tiene hasta el 22 de julio de 2025 para apelar la decisión ante un Panel de Audiencias de Nasdaq. Sin apelación, la negociación se suspenderá el 24 de julio de 2025. La compañía planea solicitar una audiencia y una suspensión de la suspensión del comercio mientras continúa con su combinación empresarial planeada con Shenzhen Qianzhi BioTechnology Co. Ltd.
Bowen Acquisition Corp (NASDAQ: BOWN)는 특수목적 인수회사로서 2025년 7월 15일 나스닥으로부터 다수의 상장 요건 위반으로 상장폐지 결정 통지를 받았습니다. 회사는 5천만 달러 이상의 최소 시가총액, 110만 주 이상의 공개 보유 주식, 1,500만 달러 이상의 공개 보유 주식 시가총액, 그리고 총 400명의 주주 요건을 충족하지 못했습니다.
BOWN은 2025년 7월 22일까지 나스닥 청문회 패널에 이 결정에 대해 항소할 수 있습니다. 항소가 없으면 2025년 7월 24일 거래가 중단됩니다. 회사는 청문회 요청과 거래 중단 유예를 신청할 계획이며, 선전 첸즈 바이오테크놀로지(Shenzhen Qianzhi BioTechnology Co. Ltd.)와의 예정된 사업 결합을 추진 중입니다.
Bowen Acquisition Corp (NASDAQ : BOWN), une société d'acquisition à vocation spécifique, a reçu une lettre de décision de radiation de la part de Nasdaq le 15 juillet 2025, en raison de multiples violations des exigences de cotation. La société n'a pas réussi à maintenir : une valeur minimale de marché de 50 millions de dollars des titres cotés, 1,1 million d'actions détenues par le public, une valeur de marché de 15 millions de dollars des actions détenues par le public, et 400 actionnaires au total.
BOWN dispose jusqu'au 22 juillet 2025 pour faire appel de la décision devant un panel d'audiences de Nasdaq. Sans appel, la négociation sera suspendue le 24 juillet 2025. La société prévoit de demander une audience et une suspension de la suspension des négociations tout en poursuivant sa combinaison d'affaires prévue avec Shenzhen Qianzhi BioTechnology Co. Ltd.
Bowen Acquisition Corp (NASDAQ: BOWN), eine Special Purpose Acquisition Company, erhielt am 15. Juli 2025 ein Schreiben von Nasdaq mit der Entscheidung zur Delistung aufgrund mehrfacher Verstöße gegen die Börsenzulassungsanforderungen. Das Unternehmen erfüllte nicht die Anforderungen: mindestens 50 Millionen US-Dollar Marktwert der gelisteten Wertpapiere, 1,1 Millionen öffentlich gehaltene Aktien, 15 Millionen US-Dollar Marktwert der öffentlich gehaltenen Aktien und insgesamt 400 Aktionäre.
BOWN hat bis zum 22. Juli 2025 Zeit, gegen die Entscheidung bei einem Nasdaq Hearing Panel Berufung einzulegen. Ohne Berufung wird der Handel am 24. Juli 2025 ausgesetzt. Das Unternehmen beabsichtigt, eine Anhörung sowie eine Aussetzung der Handelssperre zu beantragen, während es seine geplante Unternehmensfusion mit Shenzhen Qianzhi BioTechnology Co. Ltd. weiterverfolgt.
- None.
- Failed to maintain $50M minimum market value requirement
- Non-compliance with 1.1M publicly held shares requirement
- Failed to maintain $15M market value of publicly held shares
- Below required 400 total shareholders threshold
- Risk of immediate delisting if appeal is unsuccessful
- No guarantee of successful appeal or business combination completion
Insights
BOWN faces NASDAQ delisting for failing multiple listing requirements; appeals process uncertain despite pending merger.
Bowen Acquisition Corp's NASDAQ delisting notification represents a critical compliance failure across multiple listing requirements. The SPAC has fallen short on four essential metrics: insufficient market value (
This comprehensive non-compliance indicates substantial structural issues with BOWN as a public entity. While the company plans to appeal and request a suspension stay, the timeline is extremely compressed - they must file by July 22 with potential trading suspension on July 24. Even if granted a hearing, the suspension stay only provides a 15-day window unless extended.
BOWN's strategy appears to hinge entirely on completing its pending business combination with Shenzhen Qianzhi BioTechnology. However, this represents a high-risk approach with uncertain timing. The language in the release - "has been diligently attempting to consummate" - suggests potential obstacles in finalizing this transaction.
The multiple compliance failures reflect a SPAC that has likely experienced significant warrant redemptions and shareholder exits, creating a negative feedback loop where diminishing liquidity drives further shareholder departures. Without swift completion of the Shenzhen Qianzhi merger, BOWN faces probable delisting and limited options for recovery.
New York, NY, July 18, 2025 (GLOBE NEWSWIRE) -- Bowen Acquisition Corp (NASDAQ: BOWN) (“BOWN”), a special purpose acquisition company, announced that on July 15, 2025, it received a delisting determination letter (the “Delisting Determination Letter”) notifying BOWN that its securities are subject to delisting from the Nasdaq Global Market.
The Delisting Determination Letter stated that BOWN was not in compliance with (A) Nasdaq Listing Rules 5450(b)(2)(A), which requires companies listed on the Nasdaq Global Market to have Market Value of Listed Securities of at least
BOWN may appeal the Staff’s determination to a Nasdaq Hearings Panel pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. Unless BOWN requests an appeal of Nasdaq’s determination by 4:00 p.m. Eastern Time on July 22, 2025, trading of BOWN’s securities will be suspended at the opening of business on July 24, 2025, and Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission to remove BOWN’s securities from listing and registration on the Nasdaq Stock Market.
The Delisting Determination Letter also noted that a request for a hearing will stay the suspension of BOWN’s securities only for a period of 15 days from the date of the request. When BOWN requests a hearing, it may also request a stay of the suspension, pending the hearing. The hearing panel will review the request for an extended stay and notify BOWN of its conclusion as soon as is practicable, but in any event no later than 15 calendar days following the deadline to request the hearing.
BOWN intends to request a hearing before the panel to appeal the delisting determinations and to request a stay of the suspension of BOWN’s securities from trading. There can be no assurance that the panel will grant BOWN’s request for continued listing or a stay of the suspension of BOWN’s securities.
BOWN has been diligently attempting to consummate its previously announced business combination with Shenzhen Qianzhi BioTechnology Co. Ltd. BOWN believes that it will be in compliance with the listing requirements upon consummation of such transaction. However, there can be no assurance that BOWN will be able to regain compliance with the listing requirements discussed above or otherwise satisfy the other NASDAQ listing criteria.
About Bowen Acquisition Corp
Bowen Acquisition Corp is a blank check company whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. As previously disclosed, Bowen has entered into a definitive agreement for a business combination with Shenzhen Qianzhi BioTechnology Co., Ltd.
Forward Looking Statements
This press release includes certain “forward-looking” statements, as that term is defined under the federal securities laws. Actual results may differ from expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements generally are identified by the words or phrases such as “aspire,” “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “will be,” “will continue,” “will likely result,” “could,” “should,” “believe(s),” “predicts,” “potential,” “continue,” “future,” “opportunity,” seek,” “intend,” “strategy,” or the negative version of those words or phrases or similar expressions are intended to identify such forward-looking statements. You should not place undue reliance on any forward-looking statements. Any forward-looking statement speaks only as of the date hereof, and, except as required by law, the Company assumes no obligation and does not intend to update any forward-looking statement to reflect events or circumstances after the date hereof.
For investor and media inquiries, please contact:
Jiangang Luo
Chief Executive Officer
jiangangluo@bowenspac.com
FAQ
Why is Bowen Acquisition Corp (BOWN) being delisted from NASDAQ?
When will BOWN stock be suspended from trading on NASDAQ?
What options does BOWN have to prevent NASDAQ delisting?
What happens if BOWN appeals the NASDAQ delisting decision?
Can BOWN regain NASDAQ compliance through its planned merger?
